Research Letter: PDF OnlyHypophosphatemia in people living with HIV No benefit when switching from TDF to TAFSandamann, Lisaa; Stoll, Matthiasb; Behrens, Georg M.N.b,cAuthor Information aDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany bDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany cGerman Center for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany. Correspondence to Professor Georg M.N. Behrens, Department for Rheumatology and Clinical Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, D - 30625 Hannover, Germany. Tel.: +49 511 532 5337; fax: +49 511 532 5324; e-mail: [email protected] Received 11 March, 2021 Accepted 28 March, 2021 AIDS: April 06, 2021 - Volume Publish Ahead of Print - Issue - doi: 10.1097/QAD.0000000000002905 Buy PAP Metrics Abstract Treatment with tenofovir disoproxil fumarate (TDF) has been associated with hypophosphatemia mainly due to injury of the renal proximal tubulus. Studies on the impact of tenfovir alafenamid (TAF) on phosphate homeostasis in PLHIV are limited. Prompted by a patient with phosphate wasting under tenofovir but no other evidence for tubular dysfunction, a retrospective cohort analysis with 102 people living with HIV (PLHIV) revealed that hypophosphatemia remained largely unchanged after switching from TDF to TAF. Copyright © 2021 Wolters Kluwer Health, Inc.